The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
Open accessAbstract
PURPOSE: In the CLASSIC and MAGIC trials, microsatellite instability (MSI)–high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer (GC). Given the low prevalence of MSI-high status in GC and its association with other positive prognostic variables, large data sets are needed to draw robust evidence of its prognostic/predictive value. PATIENTS AND METHODS: We performed a multinational, individual-patient-data meta-analysis of the prognostic/predictive role of MSI in patients with resectable GC enrolled in the MAGIC, CLASSIC, ARTIST, and ITACA-S trials. Prognostic analyses used multivariable Cox models (MVM). The predictive role of MSI was assessed both in an all-comer population and in MAGIC and CLASSIC trials by MVM testing of the interaction of treatment (chemotherapy plus surgery v surgery) with MSI. RESULTS: MSI status was available for 1,556 patients: 121 (7.8%) had MSI-high status; 576 were European, and 980 were Asian. In MSI-high versus MSI-low/microsatellite stable (MSS) comparisons, the 5-year disease-free survival (DFS) was 71.8% (95% CI, 63.8% to 80.7%) versus 52.3% (95% CI, 49.7% to 55.1%); the 5-year overall survival (OS) was 77.5% (95% CI, 70.0% to 85.8%) versus 59.3% (95% CI, 56.6% to 62.1%). In MVM, MSI was associated with longer DFS (hazard ratio [HR], 1.88; 95% CI, 1.28 to 2.76; P < .001) and OS (HR, 1.78; 95% CI, 1.17 to 2.73; P = .008), as were pT, pN, ethnicity, and treatment. Patients with MSI-low/MSS GC benefitted from chemotherapy plus surgery: the 5-year DFS compared with surgery only was 57% versus 41% (HR, 0.65; 95% CI, 0.53 to 0.79), and the 5-year OS was 62% versus 53% (HR, 0.75; 95% CI, 0.60 to 0.94). Conversely, those with MSI-high GC did not: the 5-year DFS was 70% versus 77% (HR, 1.27; 95% CI, 0.53 to 3.04), and the 5-year OS was 75% versus 83% (HR, 1.50; 95% CI, 0.55 to 4.12). CONCLUSION: In patients with resectable primary GC, MSI is a robust prognostic marker that should be adopted as a stratification factor by clinical trials. Chemotherapy omission and/or immune checkpoint blockade should be investigated prospectively in MSI-high GCs according to clinically and pathologically defined risk of relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Note on an Exact Treatment of Contingency, Goodness of Fit and Other Problems of Significance
Freeman, G. H., & Halton, J. H. (1951) · Biometrika · doi:10.2307/2332323 · Cited by 954 · cited 5×
“33 (0) 27 (2) 25 (3) 23 (4) 19 (7) 15 (12) 4 (22) 1 (26) 88 (0) 75 (0) 68 (0) 66 (2) 48 (18) 29 (35) 17 (46) 5 (61) 422 (0) 318 (6) 238 (13) 192 (20) 163 (34) 115 (72) 68 (119) 16 (172) 1,013 (0) 845 (8) 695 (16) 628 (25) 453 (165) 300 (301) 158 (438) 36 (573) No.”
InfluentialCheong, J.-H., Yang, H.-K., Kim, H., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y.-K., Kim, H.-H., Lee, H. S., Lee, K. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30108-6 · Cited by 219
Self-citation
Research works printed but not linked: 24
- 10.1016/S0140-6736(11)61873-4 · DOI · Paper page
- 10.1056/NEJMoa055531 · DOI · Paper page
- 10.1200/JCO.2010.33.0597 · DOI · Paper page
- 10.1056/NEJMoa072252 · DOI · Paper page
- 10.1093/annonc/mdw350 · DOI · Paper page
- 10.1200/JCO.2009.27.1825 · DOI · Paper page
- 10.1093/annonc/mdt354 · DOI · Paper page
- 10.1001/jamaoncol.2016.6762 · DOI · Paper page
- 10.1097/SLA.0000000000002803 · DOI · Paper page
- 10.1159/000499628 · doi:10.1159/000499628
- 10.1200/JCO.2011.39.1953 · DOI · Paper page
- 10.1093/annonc/mdu146 · DOI
- 10.1093/biomet/38.1-2.141 · doi:10.1093/biomet/38.1-2.141 · Paper page
- 10.1002/sim.4780080504 · DOI · Paper page
- 10.1007/s10120-015-0495-y · DOI
- 10.1002/ijc.26399 · DOI · Paper page
- 10.1001/jamaoncol.2016.5469 · DOI
- 10.1200/JCO.18.01798 · DOI · Paper page
- 10.1016/S0140-6736(18)31257-1 · DOI · Paper page
- 10.1200/JCO.2011.36.2236 · DOI · Paper page
- 10.1016/S1470-2045(14)70420-6 · DOI · Paper page
- 10.1136/gutjnl-2014-308252 · DOI · Paper page
- 10.1093/jnci/djh034 · DOI · Paper page
- 10.1016/j.humpath.2012.09.009 · doi:10.1016/j.humpath.2012.09.009
Cited by
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Self-citationWang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12193 · Cited by 624
Microsatellite instability: a review of what the oncologist should know
Li, K., Luo, H., Huang, L., Luo, H., & Zhu, X. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1091-8 · Cited by 509
Muti, H. S., Heij, L. R., Keller, G., Kohlruss, M., Langer, R., Dislich, B., Cheong, J.-H., Kim, Y.-W., Kim, H., Kook, M.-C., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00133-3 · Cited by 126
Self-citation
Metadata
- Authors
- Pietrantonio, F., Miceli, R., Raimondi, A., Kim, Y. W., Kang, W. K., Langley, R. E., Choi, Y. Y., Kim, K.-M., Nankivell, M. G., Morano, F., Wotherspoon, A., Valeri, N., Kook, M.-C., An, J. Y., Grabsch, H. I., Fucà, G., Noh, S. H., Sohn, T. S., Kim, S., Di Bartolomeo, M., Cunningham, D., Lee, J., Cheong, J.-H., & Smyth, E. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-12-10
- Volume
- 37
- Issue
- 35
- Pages
- 3392-3400
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2972751531
- Cited by
- 487
- References
- 6
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. https://app.cochat.ai/papers/10.1200/jco.19.01124
- The paper
- Pietrantonio, F., Miceli, R., Raimondi, A., Kim, Y. W., Kang, W. K., Langley, R. E., Choi, Y. Y., Kim, K.-M., Nankivell, M. G., Morano, F., Wotherspoon, A., Valeri, N., Kook, M.-C., An, J. Y., Grabsch, H. I., Fucà, G., Noh, S. H., Sohn, T. S., Kim, S., . . . Smyth, E. C. (2019). Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.01124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.